search
Back to results

Modified GuiGanLongMu Decoction for Preventing Delirium in Elderly Intensive Care Unit Patients: Study Protocol

Primary Purpose

Delirium in Old Age

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
The modified GGLM decoction
A2F bundle
Sponsored by
Chongqing Traditional Chinese Medicine Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Delirium in Old Age

Eligibility Criteria

60 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Critically ill patients aged between 60 and 90 years old Had an expected total ICU length of stay (LOS) of 72 hours or more Admitted to the ICU within 48 hours before screening Signed the informed consent form. Exclusion Criteria: Incapacitation preventing the assessment of delirium (i.e., coma, sedation, or active seizures) History of psychiatric disorders, dementia, Parkinson's disease, use of antipsychotic drugs, or alcohol dependence History of traumatic brain injury or brain infection Diagnosis of delirium prior to intervention initiation Allergies to medications used in the protocol or current participation in other drug studies Inability to communicate in Chinese or English Expected to be discharged or deceased within 72 hours of admission.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Intervention group

    Control group

    Arm Description

    The modified GGLM decoction

    the A2F bundle

    Outcomes

    Primary Outcome Measures

    the prevalence of delirium
    Assessment will be performed during the study period for all enrolled participants in a timely manner using the Confusion Assessment Method for the ICU (CAM-ICU). The CAM-ICU, a 2-minute assessment tool, has proven to be quick, valid, and reliable for the diagnosis of delirium in the ICU, making it beneficial for use in both clinical and research contexts.

    Secondary Outcome Measures

    Severity of delirium
    Throughout the study, the Confusion Assessment Method-Severity scale will be administered in each included patient. The total score of the Confusion Assessment Method-Severity scale can vary between 0 and 7, where 7 indicates the most severe condition.
    Duration of delirium
    Once delirium is diagnosed, the investigators will record its duration of the patient tests positive for the Confusion Assessment Method for the ICU (CAM-ICU)

    Full Information

    First Posted
    October 17, 2023
    Last Updated
    October 20, 2023
    Sponsor
    Chongqing Traditional Chinese Medicine Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06100029
    Brief Title
    Modified GuiGanLongMu Decoction for Preventing Delirium in Elderly Intensive Care Unit Patients: Study Protocol
    Official Title
    Modified GuiGanLongMu Decoction for Preventing Delirium in Elderly Intensive Care Unit Patients: Study Protocol for a Double Blind, Randomized, Placebo-controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    November 1, 2023 (Anticipated)
    Primary Completion Date
    November 30, 2024 (Anticipated)
    Study Completion Date
    November 30, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Chongqing Traditional Chinese Medicine Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Elderly critically ill patients in the intensive care unit (ICU) are at risk of delirium, which is primarily characterized by acute consciousness impairment and perceptual, cognitive, and memory impairment, resulting in excess death, care expenditures, and acquired dementia, depression and anxiety, which severely affect the prognosis of critically ill patients. However, there are currently no effective pharmacological strategies for preventing delirium. Traditional Chinese Medicine (TCM) has extensive clinical experience in treating cognitive disorders. Therefore, we hypothesized that the use of GuiGanLongMu (GGLM) decoction, which is a classic prescription formula in traditional Chinese medicine, would reduce the incidence rate, shorten the duration and reduce the severity of delirium in ICU patients.
    Detailed Description
    This revised GGLM decoction trial was designed to be a randomized, single-center, double-blind, placebo-controlled trial. A total of 208 elderly patients from two ICUs will be randomly allocated at a 1:1 ratio to the intervention group or the control group. Both groups will receive the ABCDEF (A2F) bundle strategy recommended by guidelines, a nonpharmacological multicomponent approach including pain and delirium management, breathing trial practice, analgesic and sedation usage control, family engagement and so on, to prevent delirium. The intervention group will additionally receive revised GGLM decoction twice a day for five days, followed by a 3-month follow-up. The control group will be received placebo made of flavoring agents. The primary endpoints are the incidence, severity, and duration of delirium. Secondary endpoints include the incidence of adverse events, the length of ICU stay, the duration of physical restraint, the duration of analgesic and sedative medication, the 28-day mortality rate, and the level of anxiety and depression in patients after discharge.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Delirium in Old Age

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    166 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention group
    Arm Type
    Experimental
    Arm Description
    The modified GGLM decoction
    Arm Title
    Control group
    Arm Type
    Placebo Comparator
    Arm Description
    the A2F bundle
    Intervention Type
    Drug
    Intervention Name(s)
    The modified GGLM decoction
    Other Intervention Name(s)
    traditional Chinese medicine
    Intervention Description
    GGLM decoction, originally documented in the classic Chinese medical book "Shang Han Lun" (Treatise on Febrile Diseases), is a notable herbal formula traditionally used to calm the mind and alleviate insomnia. The modified GGLM decoction is built upon the original four herbs (Gui Zhi [Ramulus Cinnamomi], Gan Cao [Glycyrrhizae Radix et Rhizoma], Long Gu [Os Draconis], Mu Li [Ostreae Concha]) and includes targeted Chinese herbs. As soothing the mind and nourishing yin to restrain yang is the core TCM treatment principle for delirium in ICU patients, we chose targeted herbs, including Ye Jiao Teng [Fallopia multiflora], He Huan Pi [silktree (Albizia) bark], Suan Zao Ren [Ziziphi Spinosae Semen], Shi Chang Pu [Acori Tatarinowii Rhizoma], Yuan Zhi [Polygalae Radix], and Jue Ming Zi [Cassiae Semen]. The modified GGLM decoction will all be purchased by Chongqing Traditional Chinese Medicine Hospital and prepared by the Pharmacy Department, with each dose amounting to 200 g.
    Intervention Type
    Behavioral
    Intervention Name(s)
    A2F bundle
    Other Intervention Name(s)
    ABCDEF bundle
    Intervention Description
    A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
    Primary Outcome Measure Information:
    Title
    the prevalence of delirium
    Description
    Assessment will be performed during the study period for all enrolled participants in a timely manner using the Confusion Assessment Method for the ICU (CAM-ICU). The CAM-ICU, a 2-minute assessment tool, has proven to be quick, valid, and reliable for the diagnosis of delirium in the ICU, making it beneficial for use in both clinical and research contexts.
    Time Frame
    Through study completion, an average of 1 year (November 31, 2023-November 31, 2024)
    Secondary Outcome Measure Information:
    Title
    Severity of delirium
    Description
    Throughout the study, the Confusion Assessment Method-Severity scale will be administered in each included patient. The total score of the Confusion Assessment Method-Severity scale can vary between 0 and 7, where 7 indicates the most severe condition.
    Time Frame
    Through study completion, an average of 1 year (November 31, 2023-November 31, 2024)
    Title
    Duration of delirium
    Description
    Once delirium is diagnosed, the investigators will record its duration of the patient tests positive for the Confusion Assessment Method for the ICU (CAM-ICU)
    Time Frame
    Through study completion, an average of 1 year (November 31, 2023-November 31, 2024).

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    60 Years
    Maximum Age & Unit of Time
    90 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Critically ill patients aged between 60 and 90 years old Had an expected total ICU length of stay (LOS) of 72 hours or more Admitted to the ICU within 48 hours before screening Signed the informed consent form. Exclusion Criteria: Incapacitation preventing the assessment of delirium (i.e., coma, sedation, or active seizures) History of psychiatric disorders, dementia, Parkinson's disease, use of antipsychotic drugs, or alcohol dependence History of traumatic brain injury or brain infection Diagnosis of delirium prior to intervention initiation Allergies to medications used in the protocol or current participation in other drug studies Inability to communicate in Chinese or English Expected to be discharged or deceased within 72 hours of admission.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Modified GuiGanLongMu Decoction for Preventing Delirium in Elderly Intensive Care Unit Patients: Study Protocol

    We'll reach out to this number within 24 hrs